Anyone who has been taking Raptiva, a psoriasis treatment, should start heeding the US Food and Drug Administration warning. Or if you know of someone who takes this psoriasis treatment, you have to give out this FDA's advisory.

Raptiva is a treatment for mild to moderate psoriasis, a hereditary skin disorder characterized by scaly papules and plaques. Raptiva has been approved by the FDA in October 2003. However, the US FDA announced in February 2009 about Raptiva's linked to rare brain infection. There are three confirmed cases and one possible case of progressive multifocal leukoencephalopathy or PML and three, out of those four people, are now dead.

PML is a rare but sometimes fatal viral disease that occurs in people who are immunosuppressed or immunodeficient.

Genentech, the manufacturer of Raptiva, is obligated to add a Black Box Warning on Raptiva's packaging to alert physicians as well as users about the risks of PML from taking Raptiva. Thereby, the drug makers are liable for any injuries caused by Raptiva.

In this manner, you are eligible to receive money for your medical bills and other damages caused by taking Raptiva. For free, confidential initial legal consultation contact Mark & Associates by calling 1-866-50-RIGHTS (1-866-507-4448) . For detailed information about this psoriasis treatment, Raptiva, you may want to visit http://www.youhaverights.com/dangerous-drugs/raptiva